Vomiting fell to 43% from 58.5% on placebo, and Vanda plans to seek an expanded approval for GLP-1 nausea based on the results.
Recap by typeshit. Full story at Endocrinology Advisor.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
The rundown covers CagriSema, retatrutide, MariTide, VK2735 and Roche's enicepatide, which the company says cut weight by 15.5% on average in a mid-stage trial.
Zhavoronkov links recorded ARDD 2026 sessions, among them Lilly's Kevin Duffin speaking on tirzepatide and aging clocks.
A look at how the agency's interim compounding rules for peptides affect who can get them, what they cost and the safety questions involved.
The BMJ reports that the person leading the UK government's national programme for trialling new obesity treatments has received nearly £80, with the full figure behind the link.
Loading…